Amgen is halting some pricing practices that critics say were contributing to overuse of its flagship anemia drug Aranesp at a time of mounting concerns about the product’s safety. Amgen confirmed late Wednesday that it would no longer offer...

More-articles

It’s been a while since we heard much about Amgen’s struggling anemia-drug franchise. But this morning’s New York Times brings word that the company is changing a couple of pricing practices that some critics have argued encouraged overuse of the...
(Reuters) - Amgen Inc is halting some pricing practices that critics say were contributing to overuse of its flagship anemia drug Aranesp at a time of mounting concerns about the product's safety, the New York Times...